QUOTE AND NEWS
Motley Fool  Jun 10  Comment 
This cancer therapy developer's pipeline just became a lot smaller.
Motley Fool  May 10  Comment 
A late-stage trial of its once-promising pancreatic cancer treatment has come up short.
Benzinga  May 10  Comment 
Midway through trading Tuesday, the Dow traded up 1.08 percent to 17,897.68 while the NASDAQ climbed 0.83 percent to 4,789.39. The S&P also rose, gaining 0.97 percent to 2,078.63. Leading and Lagging Sectors On Tuesday, the telecommunications...
Benzinga  May 10  Comment 
Fiesta Restaurant Group Inc (NASDAQ: FRGI) shares fell 13.99 percent to reach a new 52-week low of $28.04 after the company reported weaker-than-expected Q1 earnings. NewLink Genetics Corp (NASDAQ: NLNK) shares touched a new 52-week low of...
TheStreet.com  May 9  Comment 
An experimental cancer vaccine developed by NewLink Genetics failed to prolong survival in patients with pancreatic cancer compared to a standard therapy, according to results from a phase III study disclosed Monday. NewLink shares were halted...
MarketWatch  May 9  Comment 
NewLink Genetics Corp. shares plummeted in the extended session Monday after the biotech company said its study for a pancreatic cancer drug did not reach its primary goal. NewLink shares dropped 40% to $9.97 on heavy volume after hours following...




 
TOP CONTRIBUTORS

NewLink Genetics (NASDAQ:NLNK) is a biopharmaceutical which develops drugs to help treat cancer patients.[1] The company focuses on immunotherapy - or treatment by causing the immune system to either act or cease to act. In other words, NewLink Genetics attempts to encourage the patients immune system to combat the cancerous cells rather than attempting to kill the cells directly.[2] NewLink Genetics revenues are dependent on the discovery and FDA approval of its therapies.

Business Overview

For the full year 2010, NewLink generated $2.1M in grant revenue. This was an over 100% increase from the $.9M in 2009. Since the company spends heavily on research and development, it still reported a net loss for 2010 of $16.6M. This compares to a net loss of $10.2M in 2009. [3]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on November 10, 2011. The company offered 6.2M shares each for $7. The company had already planned to sell 5.5M shares. However, since they priced below the $10-$12 range, they increased shares. The deal raised a total of $43M. The lead mangers of the deal were Stifel Financial (SF) and Canaccord Genuity.[4]

Trends & Forces

Dependence on FDA approval

As of its IPO, NewLink did not have any FDA approved drugs. It's quite clear that without a completed drug, the company will be unable to produce substantial operating revenue. As a result, the company's performance is limited to actions from the FDA. Furthermore, since NewLink is in the process of developing new, untested treatments, there is no clear guidance for the likelihood of approval or the likelihood that physicians will adopt new treatments.[5]

  1. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Overview p. 1
  2. American Cancer Society - Find Support and Treatment "Immunotherapy"
  3. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Selected Financial Data p. 51
  4. Renaissance Capital - IPO Home "NewLink Genetics prices IPO at $7, below the range" 11 Nov 2011
  5. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Risk Factors" pp. 11-15
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki